Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years.

Trial Profile

Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Lyme disease vaccine (Primary)
  • Indications Lyme disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 26 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 24 Apr 2013 Results published in a Baxter International media release and presented at the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top